Cryoport reported third quarter 2026 revenue of US$50.22 million compared to US$44.23 million a year earlier, with a wider net loss of US$10.85 million and basic loss per share of US$0.25. The business lifted full year 2026 revenue guidance to a range of US$197 million to US$199 million, highlighting confidence in demand for its services despite ongoing losses. We will now examine how Cryoport's raised 2026 revenue guidance could reshape the existing investment narrative around its growth...
Cryoport (CYRX) has become a talking point after its third quarter 2026 report, which paired higher revenue with a wider loss and an increase in full year sales guidance to US$197 million to US$199 million. The guidance hike has landed in a market that was already re-rating Cryoport, with the share price at US$20.47 after a 7.17% 1-day move and a 114.12% year-to-date share price return. The 1-year total shareholder return of 139.70% points to strong recent momentum despite a 5-year total...
If Cryoport was on your watchlist rather than in your portfolio over 2026, the outcome may feel like a missed shot. For Cryoport shareholders, the return from the start of the year was 99.8%, including dividends. That kind of move invites a hard question. Back on 1 January, when analysts were split between bullish and cautious scenarios, what clues in the firm’s role in cell and gene therapy logistics could have helped you judge whether digitalization would really translate into durable cold...
CryoPort (NASDAQ:CYRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Detailed price information for Cryoport Inc (CYRX-Q) from The Globe and Mail including charting and trades.
The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own...
This is the newest page. Registered accounts read further back.